Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.

Clinical pharmacology and therapeutics - 1 Jul 2013

Amstutz U, Ross C J D, Castro-Pastrana L I, Rieder M J, Shear N H, Hayden M R, Carleton B C

Abstract excerpt

The occurrence of hypersensitivity reactions including rare but life-threatening Stevens-Johnson syndrome (SJS) and drug-induced hypersensitivity syndrome (HSS) limits the use of the anticonvulsant carbamazepine (CBZ). Human leukocyte antigen-B (HLA)-B 15:02 and HLA-A 31:01 have been identified as predictive genetic markers for CBZ hypersensitivity in Asian and European patients. To replicate these genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Carbamazepine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Eruptions

Share to Drug Hypersensitivity

Share to Genotyping Techniques

Share to HLA-A Antigens

Share to HLA-B15 Antigen

Share to Stevens-Johnson Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 23588310
DOI: 10.1038/clpt.2013.55
PMCID: PMC3839910

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children.PMID 23588310Read ↗

The HLA-A*31:01 allele: influence on carbamazepine treatmentSemantic proximity Read ↗

The risk of cutaneous adverse reactions among patients with the <i>HLA-A* 31:01</i> allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective reviewSemantic proximity Read ↗

Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis.Semantic proximity Read ↗

HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateSemantic proximity Read ↗

HLA-B*15:21 and carbamazepine-induced Stevens-Johnson syndrome: pooled-data and in silico analysisSemantic proximity Read ↗

HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese.Semantic proximity Read ↗

HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese.Semantic proximity Read ↗

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans.Semantic proximity Read ↗

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions.Semantic proximity Read ↗

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.